Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02630966 · ClinicalTrials.gov registry record · Phase 4
Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease
A Phase 4 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
NCT02630966 is a Phase 4 study that has completed, run by Takeda. The registered enrollment target is 34 participants.
The verdict
NCT02630966, a Phase 4 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the percentage of participants with perianal fistula healing at Week 30 in 2 different dose regimens of vedolizumab intravenous (IV) 300 milligram (mg) in participants with fistulizing Crohn's disease (CD).
Interventions
- DRUG Placebo
- DRUG Vedolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-08-10 |
| Est. Completion | 2018-11-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02630966
The ClinicalTrials.gov registry entry for NCT02630966 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02630966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02630966 about?
NCT02630966 is a clinical study titled "Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease". The purpose of this study is to evaluate the percentage of participants with perianal fistula healing at Week 30 in 2 different dose regimens of vedolizumab intravenous (IV) 300 milligram (mg) in participants with fistulizing Crohn's disease (CD).
What is the current status of trial NCT02630966?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2016-08-10. Estimated completion is 2018-11-14.
What interventions are being tested in trial NCT02630966?
The interventions under investigation include: Placebo (DRUG), Vedolizumab (DRUG).
Who is sponsoring clinical trial NCT02630966?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.